Novel Therapeutic Strategies for Oral Squamous Cell Carcinoma-An Overview
Surgery, radiotherapy, and chemotherapy have been the mainstay of oral squamous cell carcinoma (OSCC) management. However, these treatments often come with significant side effects and limitations, including systemic toxicity and drug resistance. Recent advancements in therapeutic strategies for oral cancer have focused on more targeted and less invasive approaches. Some of the novel therapeutic strategies for OSCC include immunotherapy, targeted therapy, photodynamic therapy, gene therapy, phytochemicals, nanotheranostics, and CRISPR/Cas technology. These novel strategies offer promising avenues for improving the outcomes and quality of life for patients with OSCC. Ongoing research and clinical trials are essential to further refine these approaches and make them widely available.
1. Dhanuthai K, Rojanawatsirivej S, Thosaporn W, Kintarak S, Subarnbhesaj A, Darling M, et al. Oral cancer: a multicenter study. Med Oral Patol Oral Cir Bucal. 2018;23(1);e23-e29.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3): 209-49.
3. Du M, Nair R, Jamieson L, Liu Z, Bi P. Incidence trends of lip, oral cavity, and pharyngeal cancers: global burden of disease 1990-2017. J Dent Res. 2020;99(2):143-51.
4. Ljunggren HG, Jonsson R, Höglund P. Sem-inal immunologic discoveries with direct clinical implications: the 2018 nobel prize in physiology or medicine honours discoveries in cancer immunotherapy. Scand J Immunol 2018;88(6):e12731.
5. Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin Cancer Res. 2017;23(20):6165-77.
6. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med. 2015;373(1):23-34.
7. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-25.
8. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16.
9. Jiang P, Zhang Y, Archibald SJ, Wang H. Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol. 2015;28(1): 208-14.
10. Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: current and future considerations. J Oncol. 2009; 2009:346345. doi: 10.1155/2009/346345.
11. Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers (Basel). 2023;15(4):1106.
12. Liu X, Xing H, Zhang H, Liu H, Chen J. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review. Immunotherapy. 2021;13(12):989-1000.
13. Aadithi MG, Divya B, Nandhini G, Rajkumar K, Ramesh Kumar A, Sarangarajan R. Evaluation of ABCB5 immunostained epithelial stem cells in oral squamous cell carcinoma, inflammatory gingival hyperplasia and normal mucosa. Biotech Histochem. 2024;99(1):44-8.
14. Cui H, Zhang JA, Chen Chen, Liu JJ. ABC transporter inhibitors in reversing multidrug resistance to chemotherapy. Curr Drug Targets. 2015;16(12):1356-71.
15. Lee CR, Lee SH, Rigas NK, Kim RH, Kang MK, Park NH, et al. Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties. Carcinogenesis. 2016;37(2):119-28.
16. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, et al. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res. 2012;14(3):R85. doi: 10.1186/bcr3200.
17. Baniebrahimi G, Mir F, Khanmohammadi R. Cancer stem cells and oral cancer: insights into molecular mechanisms and therapeutic approaches. Cancer Cell Int. 2020;20:113. doi: 10.1186/s12935-020-01192-0.
18. Ayllón Barbellido S, Campo Trapero J, Cano Sánchez J, Perea García MA, Escudero Castaño N, Bascones Martínez A. Gene therapy in the management of oral cancer: review of the literature. Med Oral Patol Oral Cir Bucal. 2008;13(1):E15-21.
19. Indu S, Ramesh V, Oza N, Prashad KV. Gene therapy: An overview. J Orofac Sci. 2013;5(2):83-7.
20. Saraswathi TR, Kavitha B, Vijayashree Priyadharsini J. Gene therapy for oral squamous cell carcinoma: an overview. Indian J Dent Res. 2007;18(3):120-3.
21. Madalli Vijaylaxmi B, Basavaraddi Shrinivas M, Sattur A, Burde K. Gene therapy for oral squamous cell carcinoma-a promising future. Int J Inf Res Rev. 2014;1:220-2.
22. Jacob KC, Yashoda R, Puranik MP. Gene therapy in the treatment and prevention of oral cancer: an overview. Int J Adv Health Sci. 2015;2(2):14-20.
23. Sunil PM, Joseph I, Susan Varghese S. Gene therapy in oral squamous cell carcinoma - a short review. Oral Maxillofac Pathol J. 2011;2(2):142-147.
24. Lakshmi LS, Radhika T, Jeddy N. Gene therapy in oral cancer–an update J Dr NTR Univ Health Sci. 2020;9(1):1-5.
25. Westphal M, Ylä-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(9):823-33.
26. Faneca H, Düzgüne¸s N, de Lima MP. Suicide gene therapy for oral squamous cell carcinoma. Methods Mol Biol. 2019;1895:43-55.
27. Tan IB, Dolivet G, Ceruse P, Vander Poorten V, Roest G, Rauschning W. Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study. Head Neck. 2010;32(12):1597-604.
28. Kim SG, Hong JW, Boo SH, Kim MG, Lee KD, Ahn JC, et al. Combination treatment of cetuximab and photodynamic therapy in SNU-1041 squamous cancer cell line. Oncol Rep. 2009;22(4):701-8.
29. Datta SN, Allman R, Loh C, Mason M, Matthews PN. Effect of photodynamic therapy in combination with mitomycin c on a mitomycin-resistant bladder cancer cell line. Br J Cancer. 1997;76(3):312-7.
30. Saji H, Song W, Furumoto K, Kato H, Engleman EG. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy.
31. Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck.1998;20(4): 320-7.
32. Chen B, Pogue BW, Hoopes PJ, Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr. 2006;16(4):279-305.
33. Toratani S, Tani R, Kanda T, Koizumi K, Yoshioka Y, Okamoto T. Photodynamic therapy using photofrin and excimer dye laser treatment for superficial oral squamous cell carcinomas with long-term follow up. Photodiagnosis Photodyn Ther. 2016;14:104-10.
34. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, et al. Cancer prevention with natural compounds. Semin Oncol. 2010;37(3):258-81.
35. Zhang YJ, Gan RY, Li S, Zhou Y, Li AN, Xu DP, et al. Antioxidant phytochemicals for the prevention and treatment of chronic diseases. Molecules. 2015;20(12):21138-56.
36. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895-900.
37. Kuriakose MA, Ramdas K, Dey B, Iyer S, Rajan G, Elango KK, et al. A randomized double-blind placebo-controlled phase IIB trial of curcumin in oral leukoplakia. Cancer Prev Res (Phila). 2016;9(8):683-91.
38. Gu M, Jiang L, Hao L, Lu J, Liu Z, Lei Z, et al. A novel theranostic nanoplatform for imaging-guided chemo-photothermal therapy in oral squamous cell carcinoma. J Mater Chem B. 2021;9(30):6006-16.
39. Mahesh KP. Nanotheranostics-novel modality for integrating diagnosis and therapy for oral cancer. Acta Sci Dent Sci. 2018;2(9):57-8.
40. Hariharan K, Mehta T, Shah J, Dave H, Sami A, Omri A. Localized delivery of Erlotinib using liposomal gel formulations for the treatment of oral squamous cell carcinoma. Int J Pharm. 2023;642:123144.
41. Sowmya SV, Augustine D, Mushtaq S, Baeshen HA, Ashi H, Hassan RN, et al. Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing. Front Oncol. 2024;14:1383062.
42. Pan S, Su Y, Sun B, Hao R, Gao X, Han B. Knockout of CD147 inhibits the proliferation, invasion, and drug resistance of human oral cancer CAL27 cells in vitro and in vivo. Int J Biol Macromol. 2021;181:378-89.
43. Huang P, Tong D, Sun J, Li Q, Zhang F. Generation and characterization of a human oral squamous carcinoma cell line SCC-9 with CRISPR/Cas9-mediated deletion of the p75 neurotrophin receptor. Arch Oral Bio. 2017;82:223-32.
44. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-67.
45. Ciulean IS, Fischer J, Quaiser A, Bach C, Abken H, Tretbar US, et al. 250 Harnessing anti-CD44v6 CAR-NK cells for effective head and neck squamous cell carcinoma treatment. J Immunotherap Cancer. 2024;12(Suppl 2):288.
46. Lambert A, Nees L, Nuyts S, Clement P, Meulemans J, Delaere P, et al. Photodynamic therapy as an alternative therapeutic tool in functionally inoperable oral and oropharyngeal carcinoma: a single tertiary center retrospective cohort analysis. Front Oncol. 2021;11:626394.
47. Strojan P, Jesenko T, Omerzel M, Jamsek C, Groselj A, Tratar UL, et al. Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck region. Eur J Surg Oncol. 2025;51(5):109574.
48. Talreja V, Khetwani S, Nanadagopal E, Borkar NE, Khobragade K. Real-world study on the effect of nabpaclitaxel treatment on clinical outcomes and laboratory parameters in patients across metastatic tumor sites. IJMIO. 2024:9(2):46-52.